Biofortuna Ltd

biofortuna.com

Biofortuna is a leading diagnostics company offering both custom manufacturing services and molecular diagnostic products.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SUTRO BIOPHARMA DEMONSTRATES STRO-002'S IMMUNE-MODULATING PROPERTIES AT AACR 2020

Sutro Biopharma | June 22, 2020

news image

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data,...

Read More

Industrial Impact, Medical

KYMANOX ANNOUNCES ACQUISITION OF ANTERIS MEDICAL AND ANTERIS HELVETIA

Kymanox | February 06, 2023

news image

Kymanox, a leading life science-focused professional services firm, recently announced the acquisition of anteris medical GmbH and anteris helvetia AG (collectively anteris). Anteris specializes in assisting the commercialization and development of medical equipment, combination and in-vitro diagnostic products. This acquisition enables both firms to achieve their common organizational goal of geographic expansion while enhancing their service capabilities by offering clients a ...

Read More

SPPPU AND TUHH SCIENTISTS CREATES CLOSED-LOOP TECHNOLOGY FROM MICROALGAE

QS WOWNEWS | July 18, 2020

news image

Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor.According to Professor Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementati...

Read More

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

news image

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More
news image

SUTRO BIOPHARMA DEMONSTRATES STRO-002'S IMMUNE-MODULATING PROPERTIES AT AACR 2020

Sutro Biopharma | June 22, 2020

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data,...

Read More
news image

Industrial Impact, Medical

KYMANOX ANNOUNCES ACQUISITION OF ANTERIS MEDICAL AND ANTERIS HELVETIA

Kymanox | February 06, 2023

Kymanox, a leading life science-focused professional services firm, recently announced the acquisition of anteris medical GmbH and anteris helvetia AG (collectively anteris). Anteris specializes in assisting the commercialization and development of medical equipment, combination and in-vitro diagnostic products. This acquisition enables both firms to achieve their common organizational goal of geographic expansion while enhancing their service capabilities by offering clients a ...

Read More
news image

SPPPU AND TUHH SCIENTISTS CREATES CLOSED-LOOP TECHNOLOGY FROM MICROALGAE

QS WOWNEWS | July 18, 2020

Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor.According to Professor Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementati...

Read More
news image

AMUNIX RAISES $73 MILLION IN SERIES A FINANCING LED BY OMEGA FUNDS

BioSpace | March 04, 2020

Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...

Read More

Resources

resource image

Industry Outlook

Biopharmaceutical Sector

Whitepaper

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us